Posted on 13/11/2009 in Pharmaceutical Company Product News Shire has revealed that a study into its attention-deficit hyperactivity disorder (ADHD) treatment vyvanse demonstrated significant improvement in symptoms among children aged six to 12 years.
During the trial, symptoms were evaluated according to the ADHD Rating Scale IV, as well as Connors' Parent Rating Scale-Revised Short (CPRS-RS).
The study showed that patients demonstrated an improvement in emotional lability composite CPRS-RS scores while taking vyvanse compared to a placebo treatment.
Ann Childress, a study investigator and president of the Centre for Psychiatry and Behavioural Medicine, stated: "Evaluating the impact of ADHD treatments, including vyvanse, on children's emotional lability may be important for parents and healthcare professionals when assessing a child's treatment plan."
Last week, Shire revealed that the Food and Drug Administration has granted priority review status to its type 1 Gaucher therapy velaglucerase alfa and issued a definite action date of February 28th 2010 under the Prescription Drug User Fee Act.
Other news stories from 13/11/2009
Read more in the Zenopa News Archive
How this news is generated
|
